Moleculin Biotech (NASDAQ:MBRX) Stock Rating Cut to Strong Sell at Wall Street Zen

Wall Street Zen lowered shares of Moleculin Biotech (NASDAQ:MBRX) from a sell rating to a strong sell rating in a research report released on Saturday morning,Wall Street Zen reports.

Several other equities research analysts have also recently commented on MBRX. HC Wainwright dropped their price objective on Moleculin Biotech to $60.00 and set a “buy” rating on the stock in a report on Friday, August 28th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Moleculin Biotech in a research note on Thursday, October 15th. Two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $60.00.

Moleculin Biotech Trading Down 0.3%

Shares of MBRX stock opened at $8.70 on Friday. The company has a market capitalization of $8.96 million, a P/E ratio of -0.06 and a beta of 2.11. The business’s 50 day moving average is $10.45 and its two-hundred day moving average is $38.83. Moleculin Biotech has a twelve month low of $3.23 and a twelve month high of $253.05.

Moleculin Biotech (NASDAQ:MBRX) last released its quarterly earnings results on Thursday, August 13th. The company reported ($28.00) EPS for the quarter, topping the consensus estimate of ($31.00) by $3.00. As a group, equities analysts predict that Moleculin Biotech will post -47.40 earnings per share for the current fiscal year.

Moleculin Biotech Company Profile

Moleculin Biotech, Inc is a clinical-stage pharmaceutical company focused on developing treatments for cancers and other serious diseases. The company uses its proprietary technology platforms to design drug candidates intended to address treatment resistance, improve drug delivery, and target biological pathways involved in disease progression.

Moleculin’s lead program is Annamycin, a liposomal formulation of the anthracycline doxorubicin being investigated for acute myeloid leukemia and soft-tissue sarcoma.